Matthew Bain
Family Medicine · Albany, ORNPI 1851403018
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.2% of the total across 623 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 40 manufacturers, the largest accounting for just 13.6% — the pattern of someone who eats at a lot of different presentations. Among family medicine clinicians in OR with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 623 payments — averaging $18.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$2K
- Pfizer$1K
- Lilly USA, LLC$1K
- Novo Nordisk$1K
- AbbVie$885
- Boehringer Ingelheim$681
- plus $5K from 34 others
What the payments were for
- Food & beverage$11,32399%
- Education$861%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
How this compares
$11,410 in reported general payments places this provider in the 95th percentile of 1,221 family medicine providers in Oregon.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Repatha SureclickEvolocumab | 28 | $16,677 |
| FarxigaDapagliflozin Propanediol | 12 | $15,060 |
| Tresiba Flextouch U-200Insulin Degludec | 12 | $10,947 |
| EliquisApixaban | 16 | $10,845 |
| XareltoRivaroxaban | 12 | $6,458 |
| Rosuvastatin Calcium | 75 | $871 |
| Pregabalin | 18 | $771 |
| Celecoxib | 12 | $770 |
| Tamsulosin Hcl | 35 | $636 |
| Levothyroxine Sodium | 56 | $593 |
| Omeprazole | 41 | $471 |
| Nystatin | 26 | $461 |
| Testosterone Cypionate | 12 | $450 |
| Olmesartan Medoxomil | 18 | $378 |
| Metoprolol Succinate | 19 | $366 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga | $1,552 | $15,06012 claims |
| PfizerEliquis | $1,473 | $10,84516 claims |
| Johnson & JohnsonXarelto | $330 | $6,45812 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,221 family medicine providers in Oregon.
Other family medicine in Albany
- Daniel MosherAlbany$9K
- Eden MillerBend$1.7M
- Anil RajaniHood River$325K
- Stephen NelsonMedford$101K
- Karen KahnAshland$86K
- Robert GobboPortland$53K
- Kevin MillerSisters$39K
- Morris MaizelsCentral Point$25K
- Maureen MaysPortland$24K
- Nathaniel FondellMedford$21K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.